1.0808.00% ( +0.080 )
Trading: Nov 16, 11:02:21 (EDT)Valuation
Current ValuationThe current P/E ratio is -26.33, above the reasonable range, cheaper than 0% of the time in the past 1 years, and the industry ranks 148/173, the industry Median -0.64.
-26.33xP/E
$1.00Stock price
$-0.04Earnings per share
-26.33xP/E
Stock price$1.00Earnings per share$-0.04
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -41.60x
- Typical range
- -46.08x–-34.49x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
GKOSUSGlaukos | -85.36x | 90.98% | $14.49B |
BAXUSBaxter | -18.47x | 166.27% | $13.35B |
PLSEUSPulse Biosciences | -44.31x | 21.30% | $3.71B |
AXGNUSAxogen | -102.80x | 12.42% | $3.28B |
IRTCUSIRhythm | -78.52x | 16.24% | $3.03B |
ASSTUSStrive | -9.01x | 82.39% | $2.65B |
KMTSUSKestra Medical Tech | -11.20x | 0.79% | $1.68B |
BFLYUSButterfly Network | -30.29x | 36.13% | $1.63B |
ENOVUSEnovis | -3.03x | 99.88% | $1.60B |
TNDMUSTandem Diabetes | -28.45x | 80.18% | $1.40B |
NVCRUSNovocure | -11.36x | 13.66% | $1.38B |
PRCTUSPROCEPT BioRobotics | -11.92x | 0.00% | $1.37B |
DRTSUSAlpha Tau Medical | -13.35x | -- | $1.24B |
ATECUSAlphatec | -12.62x | 53.84% | $1.10B |
SIBNUSSI-BONE | -77.27x | 23.07% | $1.06B |
CBLLUSCeribell | -13.74x | 39.46% | $1.02B |
AORTUSArtivion | -52.84x | 320.41% | $931.88M |
BBNXUSBeta Bionics | -10.74x | 13.23% | $892.71M |
QDELUSQuidelOrtho | -2.00x | 72.55% | $736.90M |
SGHTUSSight Sciences | -21.20x | 25.18% | $601.92M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
